PCSK9 and hepatocellular carcinoma: As expected, treatment with PCSK9 greatly reduced cell surface LDLR expression in HepG2 hepatoma cells, whereas SV-589 cells remained highly resistant to LDLR degradation, despite similar levels of cell-association of FLAG-tagged PCSK9 (Fig. 1A).